Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel
OTCMKTS:TRUMY

Terumo 11/12/2025 Earnings Report

Terumo logo
$12.56 +0.25 (+2.03%)
As of 05/8/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

Terumo EPS Results

Actual EPS
$0.16
Consensus EPS
$0.16
Beat/Miss
Missed by -$0.00
One Year Ago EPS
N/A

Terumo Revenue Results

Actual Revenue
$1.86 billion
Expected Revenue
$1.75 billion
Beat/Miss
Beat by +$111.98 million
YoY Revenue Growth
N/A

Terumo Announcement Details

Quarter
Date
11/12/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Terumo's next earnings date is estimated for Friday, May 15, 2026, based on past reporting schedules.

Conference Call Resources

Terumo Earnings Headlines

Terumo Corporation (TRUMY) Q3 2026 Earnings Call Transcript
February 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4870046-terumo-corporation-trumy-q3-2026-earnings-call-transcript
Terumo Corporation (TRUMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
January 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4859067-terumo-corporation-trumy-presents-at-44th-annual-j-p-morgan-healthcare-conference-transcript
Move your Money Now: This has only happened 4 times in 50 years
47-year Wall Street veteran Louis Navellier says a rare market pattern is forming for only the fifth time in his career - each previous instance was triggered by a Federal Reserve shift and preceded gains of 1,100% to 2,900% in select small-cap stocks. On May 13 at 1 p.m. ET, Navellier is hosting the 10X Fed Shock Summit to walk through what he sees unfolding before the new Fed Chair takes over on May 15. Sign up and receive his 53-stock 'Exclusion List' free, plus his single highest-conviction pick named live.tc pixel
May 10 at 1:00 AM  |  Stansberry Research (Ad)
Terumo Corporation (TRUMY) Q2 2026 Earnings Call Transcript
November 12, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4842354-terumo-corporation-trumy-q2-2026-earnings-call-transcript
OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of Organ Transplantation
October 30, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/30/3177295/0/en/organox-completes-acquisition-by-terumo-corporation-to-advance-the-future-of-organ-transplantation.html
Terumo Acquiring Its Way Into The Intriguing Organ Donation Market
August 28, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4817439-terumo-stock-acquiring-way-into-intriguing-organ-donation-market
See More Terumo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Terumo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Terumo and other key companies, straight to your email.

About Terumo

Terumo (OTCMKTS:TRUMY) Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags. Through its Terumo BCT subsidiary, the company also provides apheresis, blood component management and cell therapy technologies used by blood banks, transfusion services and cell-therapy developers. Terumo’s portfolio emphasizes single-use medical devices and clinically oriented systems designed to improve procedural outcomes and patient safety.

Founded in the early 20th century and headquartered in Tokyo, Terumo has grown into a multinational supplier with operations and sales networks across Asia, the Americas and Europe. The company distributes products globally through a combination of regional subsidiaries, direct sales teams and distribution partners, serving hospitals, specialty clinics and blood centers. As a publicly listed Japanese corporation, Terumo also maintains an American depositary receipt (ADR) listing that enables trading on overseas markets.

View Terumo Profile
Earnings Tools